Search

Displaying results 9431 - 9440 of 10000 in total
  1. Drug

    Idasanutlin

    go.drugbank.com/drugs/DB12325
    Investigational

    Idasanutlin has been used in trials studying the treatment of Neoplasms, Non-Hodgkin's Lymphoma, Leukemia, Myeloid, Acute, Recurrent Plasma Cell Myeloma, and Neoplasms, Leukemia, Acute Myeloid Leukemia

  2. Drug

    Archexin

    go.drugbank.com/drugs/DB05971
    Investigational

    Synonyms: 5'-DG-DC-T-DG-DC-DA-T-DG-DA-T-DC-T-DC-DC-T-T-DG-DG-DC-DG-3', 5'-DG-DC-T-DG-DC-DA-T-DG-DA-T-DC-T-DC-DC-T-T-DG-DG-DC-DG-3', SODIUM PHOSPHOTHIOATE
  3. Drug

    Reproterol

    go.drugbank.com/drugs/DB12846
    Investigational

    Reproterol has been used in trials studying the treatment of Asthma, Exercise-Induced.

  4. Drug

    Oxelumab

    go.drugbank.com/drugs/DB16663
    Investigational

    Oxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).

  5. Drug

    BIO-11006

    go.drugbank.com/drugs/DB14886
    Investigational

    BIO-11006 is under investigation in clinical trial NCT03202394 (Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS).

  6. Drug

    (R)-acetoin

    go.drugbank.com/drugs/DB04364
    Experimental

    A product of fermentation. It is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.

    Synonyms: (R)-3-hydroxybutan-2-one
  7. Drug

    (S)-acetoin

    go.drugbank.com/drugs/DB02788
    Experimental

    A product of fermentation. It is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.

  8. Drug

    MLN576

    go.drugbank.com/drugs/DB06517
    Experimental

    XR11576 (MLN576) is a novel monophenazine with a mechanism of action that includes interaction with both topoisomerase (Topo) I and II.[A234609]

  9. Drug

    ZYCOV-D

    go.drugbank.com/drugs/DB15892
    Experimental

    The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India[A219758]. … As of August, 2020 the candidate is in Phase II clinical trials[A219758].

  10. Drug

    Candoxatril

    go.drugbank.com/drugs/DB00616
    Experimental

    Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.